ATLANTA, and TUSTIN, Calif., Sept. 7 PeregrinePharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceuticalcompany developing targeted monoclonal antibodies for the treatment of cancerand hepatitis C virus (HCV) infection, today reported new preclinical studiesshowing an equivalent of its lead antibody bavituximab significantly shrankresistant human prostate tumors in mice when added to a standard regimen ofandrogen deprivation and docetaxel. The study findings will be presentedtoday at the Innovative Minds in Prostate Cancer Today (IMPaCT) Conference inAtlanta by Dr. Yi Yin, a post-doctoral fellow in the laboratory of Dr. PhilipThorpe at UT Southwestern Medical Center in Dallas.
"These exciting results mimic the real life situation facing many prostatecancer patients whose disease is failing to respond to the standardcombination of androgen deprivation and chemotherapy drugs such as docetaxel,"said Dr. Thorpe. "In this study of human prostate tumors in mice, we haveshown that administering a bavituximab equivalent significantly enhances thetumors' response to androgen deprivation and docetaxel, with the result thatthese large resistant tumors shrank by an average of more than 50% over the13-week study. These findings further strengthen the rationale for use ofbavituximab as part of combination therapy regimens for the treatment ofprostate cancer."
Prostate cancer is the most commonly diagnosed cancer in men, accountingfor 30 percent of all male cancers, and prostate cancer is second only to lungcancer as a leading cause of male cancer deaths. Currently, there is no curefor locally advanced or metastatic prostate cancer.
"We are delighted that bavituximab shrank resistant human prostate tumorsin this study, an important new sign of its potential anti-cancer efficacy,"said Steven W. King, president and CEO of Peregrine. "Preclinically, we havenow shown that adding bavituximab equivalent antibodies to combinationregimens significantly enhances the anti-tumor activity of cancerchemotherapy, of hormone deprivation therapy and of radiation therapy inprostate, breast, lung, brain and pancreatic cancers. The breadth of thesepotential applications supports many options for future clinical studies."
Bavituximab is a monoclonal antibody that binds to a phospholipid calledphosphatidylserine that is normally located inside normal cells, but whichbecomes exposed on the outside of the cells that line the blood vessels oftumors, creating a specific target for anti-cancer treatments. Bavituximab isbelieved to help mobilize the body's immune system to destroy the bloodvessels needed for tumor growth and spread. In a Phase Ib trial in advancedcancer patients to assess its safety in combination with common chemotherapyagents, bavituximab plus chemotherapy appeared to have a safety profileconsistent with chemotherapy alone and showed positive signs of clinicalactivity, achieving objective response or disease stabilization in 50% of theevaluable patients. A protocol for a Phase II trial of bavituximab incombination with chemotherapy in patients with non-small cell lung cancer(NSCLC) is currently undergoing regulatory review in India. Bavituximab isalso in clinical trials in the U.S. in patients with advanced solid tumors andin patients co-infected with HCV and HIV.
This study, entitled "Vascular Targeting Antibody Improves Chemotherapy ofProstate Cancer" by Yi Yin, Xianming Huang, Connie Chang, Steven W. King andPhilip E. Thorpe will be presented at the Innovative Minds in Prostate CancerToday (IMPaCT) Conference in Atlanta, Georgia on September 7, 2007 at 12:30 pmEDT. This conference is being hosted by the Department of Defense ProstateCancer Research Program to showcase successes from the prostate cancerresearch being conducted with its funding.
This research was supported by the U.S. Army Medical Research and Materi